Order Article Reprints

Cansouline X, Lipan B, Sizaret D, Tallet A, Vandier C, Carmier D, Legras A. EGFR-Mutant Non-Small-Cell Lung Cancer at Surgical Stages: What Is the Place for Tyrosine Kinase Inhibitors? Cancers. 2022; 14(9):2257. https://doi.org/10.3390/cancers14092257

Cansouline, Xavier, Béatrice Lipan, Damien Sizaret, Anne Tallet, Christophe Vandier, Delphine Carmier, and Antoine Legras. 2022. "EGFR-Mutant Non-Small-Cell Lung Cancer at Surgical Stages: What Is the Place for Tyrosine Kinase Inhibitors?" Cancers 14, no. 9: 2257. https://doi.org/10.3390/cancers14092257

Cansouline, X., Lipan, B., Sizaret, D., Tallet, A., Vandier, C., Carmier, D., & Legras, A. (2022). EGFR-Mutant Non-Small-Cell Lung Cancer at Surgical Stages: What Is the Place for Tyrosine Kinase Inhibitors? Cancers, 14(9), 2257. https://doi.org/10.3390/cancers14092257